

CAMPUS AFFECTED: Peoria, Quad-Cities

AFFECTS PATIENT CARE

Please update all Providers and Staff

TEST NAME: *Clostridioides difficile* molecular tests

DATE OF CHANGE: Oct 1, 2018

SPECIMEN TYPE: Stool in Carey-Blair

OTHER USEFUL INFORMATION: Patients with a positive molecular test will remain in isolation due to colonization

Clostridioides (name change from *Clostridium*) *difficile* molecular tests will be reflexed to an antigen test for an algorithmic diagnosis of *C. difficile* disease. Any positive molecular test for *C. difficile* (stand alone or Biofire GI Panel) will be reflexed to an immunoassay antigen test. Results will be released at the same time but providers will need to check both the molecular and antigen result. The interpretations are as follows:

- Positive *C. difficile* molecular test (stand alone or GI Panel) and **negative antigen** test:

A positive molecular test for *C. difficile* with a negative toxin EIA may indicate colonization or toxin levels below the detectable limit of the assay. Clinical correlation is necessary to determine the significance of these results

- Positive *C. difficile* molecular test (stand alone or GI Panel) and **positive antigen** test:

A positive PCR result combined with a positive toxin EIA in a patient with appropriate clinical symptoms is a strong indication of *C. difficile* associated disease


For further Information Refer to UnityPoint Methodist Laboratory User Manual

For Technical Information Contact:

For Scientific and Clinical Information Contact



Scarlett Haley, Technical Coordinator - Microbiology 309-672-5525




Stephanie Burton, CLS (ASCP) Laboratory Manager 309-672-4921



Dana A Spears, Regional Director of Laboratories 309-672-4930



Lori Racsa, DO, Clinical Pathologist 309-671-2181



Elizabeth Bauer-Marsh, MD, Medical Director 309-672-4972